低价股Sutro生物制药削减成本，重新聚焦研发管线-动脉网

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

benzinga 等信源发布 2025-03-14 12:09



可切换为仅中文







On Thursday,

周四，

Sutro Biopharma, Inc.

德罗生物制药公司

STRO

prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.

优先考虑其抗体药物偶联物（ADC）管线，包括其下一代ADC管线中的三个全资拥有的临床前项目。

Exatecan ADC targeting Tissue Factor, STRO-004, will enter the clinic in the

靶向组织因子的Exatecan ADC，STRO-004，将进入临床。

second half of 2025

2025年下半年

。

STRO-006: Sutro’s differentiated integrin beta-6 ADC will enter clinical development in 2026, aimed at multiple solid tumors.

STRO-006：Sutro 公司独特的整合素 beta-6 ADC 将于 2026 年进入临床开发，针对多种实体瘤。

An IND for Sutro’s first wholly-owned dual-payload ADC is anticipated to be filed in 2027.

预计 Sutro 首个完全自主拥有的双载荷 ADC 的 IND 将于 2027 年提交。

Sutro expects operations at its manufacturing facility in San Carlos to cease by

Sutro预计其位于圣卡洛斯的制造工厂的运营将停止。

the end of 2025

2025年底

。

Additionally, the company has deprioritized additional investment in developing Luveltamab tazevibulin (luvelta, STRO-002) across all indications and is reducing headcount by nearly 50%. The company will continue to explore global out-licensing

此外，该公司已降低对开发Luveltamab tazevibulin（luvelta，STRO-002）的所有适应症的额外投资优先级，并正在裁员近50%。公司将继续探索全球对外授权机会。

opportunities for luvelta

luvelta的机会

。

As of Dec. 31, 2024, Sutro had $316.9 million in cash, cash equivalents, and marketable securities.

截至2024年12月31日，Sutro拥有3.169亿美元的现金、现金等价物和可出售证券。

The company estimates cash payments resulting from the strategic portfolio review and related restructuring to be $40 to $45 million.

公司估计，战略投资组合审查及相关重组所带来的现金支付为4000万至4500万美元。

Cost reductions subsequently realized from the restructuring, combined with refocused clinical development priorities, give the company an expected cash runway into at least the fourth quarter of 2026, excluding anticipated milestones from existing collaborations.

随后通过重组实现的成本削减，加上重新聚焦的临床开发优先事项，使该公司预计的现金跑道至少延长至2026年第四季度，不包括现有合作预期的里程碑。

The cancer-focused biotech reported a 2024 loss of $2.96 per share, up from a loss of $1.78 a year ago, missing the

这家专注于癌症的生物技术公司报告称，2024年每股亏损2.96美元，高于一年前的1.78美元，未能达到预期。

consensus of $2.92

2.92美元的共识

。

The company reported sales of $62.04 million, beating the consensus of $59. million, compared to $153.7 million a year ago, with the 2024 amount related principally to the Astellas collaboration

公司报告的销售额为 6204 万美元，超过了 5900 万美元的市场共识，而去年同期为 1.537 亿美元，其中 2024 年的金额主要与 Astellas 合作有关。

and the Tasly agreement

Tasly协议

。

Additionally, Jane Chung, President and Chief Operating Officer, will immediately assume the responsibilities of Chief Executive Officer and Board member.

此外，Jane Chung总裁兼首席运营官将立即承担首席执行官和董事会成员的职责。

Price Action:

价格行为:

STRO stock is down 24% at $0.95 at the last check Friday.

STRO股票在上周五的最后一次检查中下跌了24%，至0.95美元。

Read Next:

接下来阅读：

Specialty Retailer Buckle Q4: Sales Dip, Earnings Beat, Solid Comps And More

专业零售商Buckle第四季度：销售额下降，利润超预期，同店销售表现强劲等

Image: Shutterstock

图片：Shutterstock

STRO